Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2016-08-30 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
补充公告
Regulatory Filings Classification · 95% confidence The document is a supplementary announcement by the board of 中源协和细胞基因工程股份有限公司 regarding previously disclosed announcements about guarantees and related party transactions. It provides detailed financial and operational information about related parties and clarifies relationships and independence. The document is relatively short (2167 characters) and serves as a supplemental disclosure to prior announcements rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed management analysis. It is not a certification or officer attestation. The content fits best with a Regulatory Filing (RNS) as it is a regulatory disclosure supplementing prior announcements without constituting a full report or announcement of voting results, capital changes, or management changes.
2016-08-30 Chinese
独立董事提名人声明
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the company's board. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There is no financial data, no report of financial results, no voting results, no announcement of a meeting, no legal proceeding update, and no mention of any other report type. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is a standalone statement, not an announcement of a report publication or regulatory filing. Confidence is high due to clear content focus on board nomination.
2016-08-29 Chinese
独立董事关于关联交易事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on related party transactions, referencing compliance with regulatory guidelines and company governance rules. It discusses the legality and fairness of specific related party transactions and the board's approval process. The document is a formal opinion letter rather than a full financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a certification or a brief announcement. It fits best as a Regulatory Filing (RNS) because it is a compliance-related disclosure that does not fit other specific categories like Audit Report or Board/Management Information.
2016-08-29 Chinese
关于控股子公司中源协和基因科技有限公司与中国银宏有限公司签署合作协议书暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party transaction between the company's subsidiary and another company controlled by the same ultimate controller. It details the cooperation agreement, transaction pricing, approval procedures, and the impact on the company. There are no financial statements or comprehensive financial data presented. The document is a formal announcement of a related party transaction, which is a regulatory disclosure but does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive information about the transaction itself. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2016-08-29 Chinese
关于投资设立中源协和生物细胞存储服务有限公司的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the establishment of a new subsidiary company for investment purposes. It details the investment amount, business scope, board and management arrangements, and the strategic rationale behind the investment. There are no financial statements, quarterly or annual results, or audit information presented. The document is relatively short (1166 characters) and focuses on a corporate action related to capital allocation and business expansion. This fits the category of Capital/Financing Update (CAP), as it reports on a new investment and capital deployment by the company.
2016-08-29 Chinese
关于为关联方提供担保暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding providing guarantees for related parties and related party transactions. It details the guarantee amount, parties involved, board approvals, and legal risks. It does not contain financial statements or detailed financial performance data. The document is a formal disclosure about a specific corporate action (providing guarantees to related parties) and is regulatory in nature. It is not an annual report, earnings release, or any financial report. It fits the category of a regulatory announcement about a related party transaction and guarantee provision. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is under 5,000 characters and is a standalone announcement, not a report publication announcement or certification letter.
2016-08-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.